Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease
Open Access
- 1 April 2012
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Journal of Applied Oral Science
- Vol. 20 (2) , 128-138
Abstract
Recently, new treatment approaches have been developed to target the host component of periodontal disease. This review aims at providing updated information on host-modulating therapies, focusing on treatment strategies for inhibiting signal transduction pathways involved in inflammation. Pharmacological inhibitors of MAPK, NFκB and JAK/STAT pathways are being developed to manage rheumatoid arthritis, periodontal disease and other inflammatory diseases. Through these agents, inflammatory mediators can be inhibited at cell signaling level, interfering on transcription factors activation and inflammatory gene expression. Although these drugs offer great potential to modulate host response, their main limitations are lack of specificity and developments of side effects. After overcoming these limitations, adjunctive host modulating drugs will provide new therapeutic strategies for periodontal treatment.Keywords
This publication has 93 references indexed in Scilit:
- Invasive oral aspergillosis in a patient with acute myeloid leukaemiaAustralian Dental Journal, 2010
- Signaling pathways associated with the expression of inflammatory mediators activated during the course of two models of experimental periodontitisLife Sciences, 2009
- Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Receiving Antiretroviral TherapyDrugs, 2008
- MAPKs and their relevance to arthritis and inflammationRheumatology, 2007
- A dominant function of p38 mitogen‐activated protein kinase signaling in receptor activator of nuclear factor‐κB ligand expression and osteoclastogenesis induction by Aggregatibacter actinomycetemcomitans and Escherichia coli lipopolysaccharideJournal of Periodontal Research, 2007
- Genetic Deficiency of p38α Reveals its Critical Role in Myoblast Cell Cycle Exit:The p38α-JNK ConnectionCell Cycle, 2007
- Mitogen activated protein kinase inhibitors: where are we now and where are we going?Annals of the Rheumatic Diseases, 2006
- Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammationCurrent Opinion in Pharmacology, 2004
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- A protein tyrosine kinase in the interferon αβ signaling pathwayCell, 1992